Last reviewed · How we verify
NCT06901336
A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants
Phase 1 trial testing [14C]-STX-478 in Healthy in 8 participants. Completed in 6 May 2025.
6 May 2025
Quick facts
| Lead sponsor | Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 8 |
| Start date | 20 March 2025 |
| Primary completion | 6 May 2025 |
| Estimated completion | 6 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- [14C]-STX-478 — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company — full company profile →
Who can join
Adults 18 to 55, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is to conduct blood tests to measure how much STX-478 is in the bloodstream and how the body handles and eliminates it in healthy participants. This study will involve a single dose of 14C radiolabeled STX-478. This means that a radioactive tracer substance, C14, will be incorporated into the study drug STX-478 to investigate the study drug and its breakdown products and to find out how much of these passes from blood into urine, feces and expired air. The study will also evaluate the safety and tolerability of STX-478.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies.
Schmitz AE, Udgata S, Johnson KA, Deming DA. · · 2025 · cited 5× · PMID 40564038 · DOI 10.3390/biomedicines13061319
Verify or expand the search:
- PubMed search for NCT06901336
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company trials
Trials by the same sponsor.
- NCT06991179 — A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06901336 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
- Last refreshed: 25 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06901336.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing